JR von P schreef op 22 januari 2018 09:34:
even voorstellen, ik ben JR
Dit is de eerste keer dat ik hier post, ik heb sinds een jaar of 8 aandeeltjes pharming, maar liefts 1400 bij de RABO, deze zijn eindelijk winstgevend, begin october heb ik 95.000 bijgekocht via Binck, deze zijn... winstgevend :)
Toch zijn die 1400 bij de RABO de reden dat ik Pharming altijd ben blijven volgen.. gelukkig wel dus.
Dit forum volg ik overigens al weer sinds oktober dagelijks, mijn dank voor alle info en input.
Ik heb meteen een vraagje cq opmerking, hier een link naar de Pharming website.www.pharming.com/science/#expanding-b...
en dan trok dit specifieke deel mijn aandacht, ik kan me niet herrineren dat dit er eerder opstond.
Transgenic Production Technology Platform (TPTP)
After the discovery of DNA and recombinant DNA techniques in the past decades it became possible to transfer genes between different organisms, such as plants and bacteria. Scientists discovered how to transfer mammalian genes into the genetic material of other animals, and breed transgenic animals with specific (mixed) characteristics. This new scientific approach of recombining genetic material from different biological sources became known as recombinant DNA technology and the animals generated with such technology as transgenic animals.
Therapeutic proteins from milk
Pharming’s predecessor company GenPharm was founded to commercialize this innovative technology. The Pharming scientists were able to breed animals that could produce human-like proteins in their milk. The company further improved this technology and made it fully compliant with regulatory guidelines that apply in the United States and Europe.
For commercial purposes, Pharming also developed large scale purification methods for separating the human proteins from the other natural components in milk. The purification process for our lead product Ruconest was successfully up-scaled and transferred to the current manufacturing partner Sanofi Chimie. All production facilities and processes comply with regulatory GMP-guidelines and are suitable for large-scale production of the highest quality pharmaceutical products.
High quality in sufficient quantity
Pharming can produce complex therapeutic proteins in the mammary glands of rabbits or cattle and purify the protein from milk for its therapeutic application. This production method has the advantage of delivering high quality human proteins in sufficient quantities and consistently high quality. Pharming is the first company in the world to obtain regulatory approval for a recombinant protein pharmaceutical produced in milk of transgenic rabbits. The technology platform has been developed such that consistency of the product attributes is easily maintained through scaling up of the production process. Furthermore the transgenic rabbit platform has been optimized by Pharming to produce large quantities of recombinant proteins in a controlled, easily transferrable and scalable fashion.
There is a need in the industry for new means to produce over 900 protein therapeutics that are currently in development. Pharming believes that its production technology offers significant competitive advantages and will enable the development of better, safer and more cost-effective therapeutic products.
As of July 2013, Pharming has partnered the technology platform with The Shanghai Institute of Pharmaceutical Industry (SIPI); a Sinopharm Company.
This strategic collaboration for the development, manufacture and commercialization of new products based on Pharming’s technology platform, allows SIPI access to Pharming’s technology and know-how such that a joint global development of new products can benefit both parties.
Betekend dit nu dat ze niet zo zeer hun medicijnen maar meer hun platform als de toekomst van Pharming zien ??
Met vriendelijke groet.